DK3504241T3 - Anti-cd3-antistofformuleringer - Google Patents
Anti-cd3-antistofformuleringer Download PDFInfo
- Publication number
- DK3504241T3 DK3504241T3 DK17765519.8T DK17765519T DK3504241T3 DK 3504241 T3 DK3504241 T3 DK 3504241T3 DK 17765519 T DK17765519 T DK 17765519T DK 3504241 T3 DK3504241 T3 DK 3504241T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380652P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/049211 WO2018044948A1 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3504241T3 true DK3504241T3 (da) | 2024-08-19 |
Family
ID=59858782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17765519.8T DK3504241T3 (da) | 2016-08-29 | 2017-08-29 | Anti-cd3-antistofformuleringer |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10688186B2 (enExample) |
| EP (2) | EP3504241B1 (enExample) |
| JP (3) | JP7057360B2 (enExample) |
| CN (2) | CN116617387A (enExample) |
| AU (2) | AU2017319318B2 (enExample) |
| CA (1) | CA3032596A1 (enExample) |
| DK (1) | DK3504241T3 (enExample) |
| ES (1) | ES2986900T3 (enExample) |
| IL (2) | IL301948B2 (enExample) |
| WO (1) | WO2018044948A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3504241B1 (en) | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
| WO2018226833A1 (en) * | 2017-06-06 | 2018-12-13 | The Brigham And Women's Hospital, Inc. | Methods of suppressing microglial activation |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3863621A4 (en) * | 2018-10-09 | 2022-08-24 | Monash University | COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE AND INFLAMMATION DISEASES |
| EP3873521A2 (en) * | 2018-10-31 | 2021-09-08 | Tiziana Life Sciences PLC | Composition and methods of treating inflammatory and autoimmune diseases |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| WO2021035054A1 (en) | 2019-08-20 | 2021-02-25 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| JP2023517611A (ja) * | 2020-03-10 | 2023-04-26 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20230227555A1 (en) * | 2020-07-30 | 2023-07-20 | Tiziana Life Sciences Plc | Cd-3 antibodies for the treatment of coronavirus |
| MX2023001238A (es) * | 2020-07-31 | 2023-03-03 | Glaxosmithkline Ip Dev Ltd | Proteina de union a antigeno. |
| US20220332822A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CA3251421A1 (en) * | 2022-05-13 | 2023-11-16 | Tiziana Life Sciences Plc | FORALUMAB NASAL FORMULATIONS |
| CN119948056A (zh) * | 2022-07-27 | 2025-05-06 | 塞尔德克斯医疗公司 | 抗kit抗体制剂和方法 |
| EP4583878A1 (en) | 2022-09-09 | 2025-07-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
| JP2026514293A (ja) | 2023-02-08 | 2026-05-08 | イムノス セラピューティクス アーゲー | β２ミクログロブリン、ＨＬＡ重鎖ポリペプチド及びＣＤ４７－ＳＩＲＰαの阻害剤の融合タンパク質 |
| TW202448505A (zh) | 2023-03-01 | 2024-12-16 | 美商普泛森生技公司 | 用於治療第1型糖尿病的方法及組成物 |
| JP7548475B1 (ja) * | 2023-03-16 | 2024-09-10 | 小野薬品工業株式会社 | 抗体製剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235583A1 (en) | 2002-06-14 | 2003-12-25 | Jeppe Sturis | Combined use of a modulator of CD3 and a beta cell resting compound |
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| US7883703B2 (en) * | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| AU2006291005A1 (en) | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| KR20110047255A (ko) * | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체 |
| MX2011013722A (es) | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CA2778331A1 (en) * | 2009-10-20 | 2011-04-28 | Aoife Brennan | Methods of using anti-cd3 antibodies to prevent weight gain |
| EP2490714A4 (en) * | 2009-10-20 | 2013-11-13 | Glaxo Group Ltd | ASSAY OF ANTI-CD3 ANTIBODIES IN AUTOIMMUNE DISEASES |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| US20120189621A1 (en) * | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP3504241B1 (en) | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
-
2017
- 2017-08-29 EP EP17765519.8A patent/EP3504241B1/en active Active
- 2017-08-29 DK DK17765519.8T patent/DK3504241T3/da active
- 2017-08-29 ES ES17765519T patent/ES2986900T3/es active Active
- 2017-08-29 JP JP2019531579A patent/JP7057360B2/ja active Active
- 2017-08-29 CN CN202211674110.7A patent/CN116617387A/zh active Pending
- 2017-08-29 CN CN201780052970.8A patent/CN109843920B/zh active Active
- 2017-08-29 CA CA3032596A patent/CA3032596A1/en active Pending
- 2017-08-29 AU AU2017319318A patent/AU2017319318B2/en active Active
- 2017-08-29 WO PCT/US2017/049211 patent/WO2018044948A1/en not_active Ceased
- 2017-08-29 US US15/690,192 patent/US10688186B2/en active Active
- 2017-08-29 IL IL301948A patent/IL301948B2/en unknown
- 2017-08-29 EP EP24175798.8A patent/EP4406554A3/en active Pending
- 2017-08-29 IL IL264502A patent/IL264502B2/en unknown
-
2020
- 2020-05-18 US US16/876,839 patent/US20210000957A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063973A patent/JP7461401B2/ja active Active
-
2024
- 2024-03-22 JP JP2024046063A patent/JP2024075713A/ja active Pending
- 2024-12-16 AU AU2024278457A patent/AU2024278457A1/en active Pending
-
2025
- 2025-02-07 US US19/048,132 patent/US20250228946A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3504241B1 (en) | 2024-05-15 |
| US20250228946A1 (en) | 2025-07-17 |
| CA3032596A1 (en) | 2018-03-08 |
| ES2986900T3 (es) | 2024-11-13 |
| CN109843920B (zh) | 2023-01-13 |
| IL264502A (en) | 2019-02-28 |
| AU2024278457A1 (en) | 2025-01-09 |
| US20210000957A1 (en) | 2021-01-07 |
| EP4406554A3 (en) | 2024-10-30 |
| IL301948A (en) | 2023-06-01 |
| IL301948B2 (en) | 2024-09-01 |
| JP2019526627A (ja) | 2019-09-19 |
| EP4406554A2 (en) | 2024-07-31 |
| EP3504241A1 (en) | 2019-07-03 |
| JP7461401B2 (ja) | 2024-04-03 |
| CN109843920A (zh) | 2019-06-04 |
| JP2022082757A (ja) | 2022-06-02 |
| IL264502B2 (en) | 2023-09-01 |
| US10688186B2 (en) | 2020-06-23 |
| IL264502B1 (en) | 2023-05-01 |
| CN116617387A (zh) | 2023-08-22 |
| IL301948B1 (en) | 2024-05-01 |
| JP2024075713A (ja) | 2024-06-04 |
| JP7057360B2 (ja) | 2022-04-19 |
| WO2018044948A1 (en) | 2018-03-08 |
| AU2017319318A1 (en) | 2019-02-21 |
| US20180177880A1 (en) | 2018-06-28 |
| AU2017319318B2 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1022I2 (fr) | Anticorps anti-pd-1 | |
| IL264502A (en) | Anti-CD3 antibody formulations | |
| IL263764A (en) | Anti-cd19 antibody formulations | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| EP3498840A4 (en) | ANTI-LAG-3 ANTIBODY | |
| EP3423089A4 (en) | ANTI-Tigit ANTIBODY | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| MA46272A (fr) | Anticorps anti-cd27 | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| DK3529269T3 (da) | Antistof-konstruktioner | |
| IL256097A (en) | Antibody epitope | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| EP3383915A4 (en) | PD-1 ANTIBODY | |
| DK3484446T3 (da) | Antistofsammensætninger | |
| EP3492591A4 (en) | ANTI-B7-H4 ANTIBODIES | |
| EP3526247A4 (en) | Anti-il1-rap antibodies | |
| EP3399992A4 (en) | SELF-NETWORKING ANTIBODIES | |
| EP3484919A4 (en) | ANTIBODIES AGAINST AMYLOID BETA | |
| MA42843A (fr) | Anticorps anti-cd115 | |
| DK3481420T3 (da) | Antistofformuleringer | |
| EP3336185A4 (en) | ANTIBODY | |
| IL283886A (en) | Antibody formulations |